Role of organic cation transporter-1 (OCT-1) in drug resistance condition of ph plus chronic myeloid leukemia (CML)

被引：0
|
作者：
Patel, Saumya [1 ]
Shah, Krupa [2 ]
Rawal, Rakesh [1 ]
机构：
[1] Gujarat Univ, Ahmadabad, Gujarat, India
[2] Gujarat Canc Res Inst, Ahmadabad, Gujarat, India
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-2106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2106
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells
    C Arimany-Nardi
    A Montraveta
    E Lee-Vergés
    X S Puente
    H Koepsell
    E Campo
    D Colomer
    M Pastor-Anglada
    The Pharmacogenomics Journal, 2015, 15 : 363 - 371
  • [42] Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells
    Arimany-Nardi, C.
    Montraveta, A.
    Lee-Verges, E.
    Puente, X. S.
    Koepsell, H.
    Campo, E.
    Colomer, D.
    Pastor-Anglada, M.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (04): : 363 - 371
  • [43] Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response Reply
    Marin, David
    Goldman, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1145 - 1146
  • [44] NILOTINIB (TASIGNA) THERAPY POST ALLOGENEIC STEM CELL TRANSPLANTATION (ALLoSCT) FOR ADVANCED (>CP1) CHRONIC MYELOID LEUKEMIA (CML) AND PH plus ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Nagler, A.
    Volchek, Y.
    Varda-Bloom, N.
    Somech, R.
    Yerushalmi, R.
    Shimoni, A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S365 - S365
  • [45] Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells
    Buss, I.
    Hamacher, A.
    Sarin, N.
    Kassack, M. U.
    Kalayda, G. V.
    METALLOMICS, 2018, 10 (03) : 414 - 425
  • [46] CYTOGENETIC STUDIES OF EARLY MYELOID PROGENITOR COMPARTMENTS IN PH1-POSITIVE CHRONIC MYELOID-LEUKEMIA (CML) .1. PERSISTENCE OF PH1-NEGATIVE COMMITTED PROGENITORS THAT ARE SUPPRESSED FROM DIFFERENTIATING INVIVO
    DUBE, ID
    GUPTA, CM
    KALOUSEK, DK
    EAVES, CJ
    EAVES, AC
    BRITISH JOURNAL OF HAEMATOLOGY, 1984, 56 (04) : 633 - 644
  • [47] Role of Hum an Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions
    Arimany-Nardi, Cristina
    Minuesa, Gerard
    Keller, Thorsten
    Erkizia, Itziar
    Koepsell, Hermann
    Martinez-Picado, Javier
    Pastor-Anglada, Marcal
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [48] ALTERATIONS OF THE BREAKPOINT CLUSTER REGION (BCR) GENE IN PHILADELPHIA (PH1) POSITIVE AND NEGATIVE CHRONIC MYELOID-LEUKEMIA (CML)
    JANUSZEWICZ, EH
    GARGANO, JA
    SHERRITT, M
    BERNARD, CCA
    OMALLEY, FM
    GARSON, OM
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1988, 18 (03): : 425 - 425
  • [49] Maintenance Therapy with Nilotinib (Tasigna) Post Allogeneic Stem Cell Transplantation (AlloSCT) for Advanced (>CP1) Chronic Myeloid Leukemia (CML) and Ph plus Acute Lymphoblastic Leukemia (ALL)
    Nagler, Arnon
    Volchek, Yulia
    Bloom, Nira
    Somech, Raz
    Yerushalmi, Ronit
    Shimoni, Avichai
    BLOOD, 2011, 118 (21) : 878 - 879
  • [50] Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia
    Wang, L.
    Giannoudis, A.
    Lane, S.
    Williamson, P.
    Pirmohamed, M.
    Clark, R. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 258 - 264
12345